MassBiologics sent lawmakers its annual account of fiscal year 2026 work, finances, agreements, and its developing plans for future operations.
MassBiologics submitted its annual report to the Massachusetts Legislature, covering its work, agreements, finances, and plans.
MassBiologics says it is developing a business plan focused on gene therapy manufacturing and the specialized skills that work requires.
The report says MassBiologics will add budget and forecast information later, after the University completes those projections.
MassBiologics reports on its operations and finances to the Massachusetts Legislature. The report covers the University of Massachusetts’ MassBiologics laboratories and their activities during fiscal year 2026. The report covers July 1, 2025, through June 30, 2026, and is dated September 30, 2026.
MassBiologics states that its future business plan is under development and describes plans to focus on biologics for gene therapy. The plan concerns MassBiologics’ work in biologics manufacturing. The report does not give a date for completing the plan.
MassBiologics says it will provide an amended report with its FY27 budget and later projections when they are complete. The updates concern the FY27 budget and projections for FY28 through FY31. The FY27 first-quarter projection was expected after September 30, 2026, for presentation in December; the FY28–FY31 forecast will be added when complete.
No hearings or votes scheduled.